“merck-kgaa” Archives

Entry Author Date Location
Clinical Data Stock Surging on FDA Approval of Anti-Depression Drug 01/24/11 Boston
Sproxil Eyes VC Funding and New Customers for Its Technology for Fighting Medication Counterfeiting 01/18/11 Boston
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug 01/10/11 Seattle
Nano-Terra Takes in $17.2M for Nanotech Development 12/14/10 Boston
Quanterix Adds Former Millipore CEO as Chair 12/01/10 Boston
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline 07/14/10 Seattle
Ambrx CEO Steve Kaldor Departs 07/12/10 San Diego
Oncothyreon Lines Up $20M 07/07/10 Seattle
Seattle Genetics’ Dark Horse, Gilead Beats Novartis, Oncothyreon Back in the Saddle, & More Seattle-Area Life Sciences News 06/24/10 Seattle
Oncothyreon’s Cancer Vaccine Back in the Saddle, as Merck KGaA Re-Starts Clinical Trials 06/17/10 Seattle
Counterfeit Medicine Fighter Sproxil Declared Winner at IBM SmartCamp Event Spotlighting Technology that Improves the Physical World 06/04/10 Boston
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market 05/11/10 Boston
Dendreon Makes History: FDA Approves First Active Immune-Booster to Fight Cancer 04/29/10 Seattle
Oncothyreon Stock Plummets as Side Effect Emerges in Cancer Patient, Trials Halted 03/23/10 Seattle
Avila Sets Out to Take on Vertex, CombinatoRx Nails FDA Approval, Millipore Opts for Merck KGaA over Thermo Fisher, & More Boston-Area Life Sciences News 03/05/10 Boston
Merck to Move U.S. Chem. Unit to Bay State 03/04/10 Boston
Marathon and Zafgen Add to Series B Rounds, Athenahealth and Sermo Announce Partnership, Sensata Sets IPO Terms, & More Boston-Area Deals News 03/03/10 Boston
Millipore To March Down the Aisle with Merck KGaA, Not Thermo Fisher 03/01/10 Boston
San Diego’s Tioga Pharmaceuticals Raises $18 Million to Develop IBS Drug 02/17/10 San Diego
Winshuttle Expands to Germany with Acquisition, Keeps Growing Through the Recession 02/16/10 Seattle
Flexion Snags Pfizer Bucks, Three Pharma Deals, For New Drug Model 01/29/10 Boston
Vertex’s Matt Emmens on His Journey From Security Guard to CEO 01/27/10 Boston
Tysabri’s PML Count Climbs to 28, and Some Reflections From Biogen Idec’s Departing CEO 01/06/10 Boston
Oncothyreon CEO on Next-Generation Cancer Vaccines, Two Key Zymonites, and Serious Luck 12/23/09 Seattle
Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle Genetics Finds New Partner, & More Seattle-Area Life Sciences News 12/17/09 Seattle
Oncothyreon Partner Starts New Lung Cancer Trial, Prompts Takeover Scuttle 12/10/09 Seattle
Forma Gets a $25.5M Fix, Novartis Bids Idera Adieu, Alnylam CEO Talks Strategy, & More Boston-Area Life Sciences News 12/02/09 Boston
Novartis Parts Ways with Idera Pharma 11/25/09 Boston
AVI Settles In, ZymoGenetics MS Drug Fails, Dendreon’s FDA Filing Set for Mid-November & More Seattle-Area Life Sciences News 10/01/09 Seattle
ZymoGenetics Partner Halts Multiple Sclerosis Trials After Drug Fails 09/28/09 Seattle
Page 2 of 3 « previous page · next page »